These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22534020)

  • 21. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra.
    Han BS; Iacovitti L; Katano T; Hattori N; Seol W; Kim KS
    Neurosci Lett; 2008 Sep; 442(3):190-4. PubMed ID: 18634852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain.
    Melrose H; Lincoln S; Tyndall G; Dickson D; Farrer M
    Neuroscience; 2006; 139(3):791-4. PubMed ID: 16504409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons.
    Schildt A; Walker MD; Dinelle K; Miao Q; Schulzer M; O'Kusky J; Farrer MJ; Doudet DJ; Sossi V
    J Parkinsons Dis; 2019; 9(1):121-139. PubMed ID: 30452424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.
    Lee JW; Tapias V; Di Maio R; Greenamyre JT; Cannon JR
    Neurobiol Aging; 2015 Jan; 36(1):505-18. PubMed ID: 25174649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
    Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
    Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.
    Qin Q; Zhi LT; Li XT; Yue ZY; Li GZ; Zhang H
    CNS Neurosci Ther; 2017 Feb; 23(2):162-173. PubMed ID: 27943591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families.
    Ohta E; Hasegawa K; Gasser T; Obata F
    Neurosci Lett; 2007 Apr; 417(1):21-3. PubMed ID: 17395370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila.
    Lee SB; Kim W; Lee S; Chung J
    Biochem Biophys Res Commun; 2007 Jun; 358(2):534-9. PubMed ID: 17498648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
    Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ
    PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
    Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
    Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leucine-rich repeat kinase 2 associates with lipid rafts.
    Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
    Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
    Skiteva O; Yao N; Sitzia G; Chergui K
    J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.